Ever Supreme Bio Technology Co., Ltd (TPEX:6712)
Taiwan
· Delayed Price · Currency is TWD 129.00
0.00 (0.00%)
Apr 29, 2026, 1:30 PM CST
TPEX:6712 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,018 | 933.81 | 758.39 | 627.51 | 438.84 | Upgrade
|
| Revenue Growth (YoY) | 8.96% | 23.13% | 20.86% | 42.99% | 521.61% | Upgrade
|
| Cost of Revenue | 296.18 | 273.77 | 273.64 | 212.96 | 193.36 | Upgrade
|
| Gross Profit | 721.33 | 660.04 | 484.75 | 414.56 | 245.48 | Upgrade
|
| Selling, General & Admin | 44.23 | 47.18 | 47.91 | 40.07 | 45.14 | Upgrade
|
| Research & Development | 238.16 | 147.22 | 99.11 | 90.69 | 84.14 | Upgrade
|
| Other Operating Expenses | - | 44.38 | - | - | - | Upgrade
|
| Operating Expenses | 282.33 | 238.85 | 147.02 | 130.76 | 129.28 | Upgrade
|
| Operating Income | 439 | 421.19 | 337.73 | 283.8 | 116.2 | Upgrade
|
| Interest Expense | -0.92 | -0.13 | -0.2 | -0.51 | -0.62 | Upgrade
|
| Interest & Investment Income | 27.97 | 10.89 | 14.18 | 9.88 | 6 | Upgrade
|
| Earnings From Equity Investments | -9.25 | 52.09 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 21.76 | -30.72 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 28.8 | 23.31 | 7.52 | 7.35 | 4.27 | Upgrade
|
| EBT Excluding Unusual Items | 485.61 | 507.35 | 380.99 | 269.79 | 125.85 | Upgrade
|
| Gain (Loss) on Sale of Investments | 38.73 | -46.68 | 241.86 | -5.7 | 261.05 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0 | 11.33 | Upgrade
|
| Asset Writedown | - | - | - | - | -1.94 | Upgrade
|
| Other Unusual Items | 0 | 0.08 | 0.17 | 0.01 | 0.52 | Upgrade
|
| Pretax Income | 524.33 | 460.74 | 623.01 | 264.1 | 396.82 | Upgrade
|
| Income Tax Expense | 94.9 | 93.49 | 83.62 | 63.39 | 27.22 | Upgrade
|
| Net Income | 429.43 | 367.25 | 539.4 | 200.71 | 369.6 | Upgrade
|
| Net Income to Common | 429.43 | 367.25 | 539.4 | 200.71 | 369.6 | Upgrade
|
| Net Income Growth | 16.93% | -31.91% | 168.74% | -45.69% | - | Upgrade
|
| Shares Outstanding (Basic) | 88 | 89 | 90 | 91 | 90 | Upgrade
|
| Shares Outstanding (Diluted) | 88 | 89 | 90 | 91 | 91 | Upgrade
|
| Shares Change (YoY) | -0.92% | -1.68% | -1.01% | 0.15% | 11.01% | Upgrade
|
| EPS (Basic) | 4.88 | 4.14 | 5.99 | 2.21 | 4.10 | Upgrade
|
| EPS (Diluted) | 4.88 | 4.14 | 5.97 | 2.20 | 4.06 | Upgrade
|
| EPS Growth | 17.92% | -30.71% | 171.70% | -45.83% | - | Upgrade
|
| Free Cash Flow | 535.07 | 435.49 | 415.92 | 316.02 | 133.7 | Upgrade
|
| Free Cash Flow Per Share | 6.08 | 4.91 | 4.61 | 3.46 | 1.47 | Upgrade
|
| Dividend Per Share | 3.500 | 4.545 | 4.959 | 1.503 | 3.416 | Upgrade
|
| Dividend Growth | -23.00% | -8.33% | 229.89% | -56.00% | - | Upgrade
|
| Gross Margin | 70.89% | 70.68% | 63.92% | 66.06% | 55.94% | Upgrade
|
| Operating Margin | 43.14% | 45.11% | 44.53% | 45.23% | 26.48% | Upgrade
|
| Profit Margin | 42.20% | 39.33% | 71.12% | 31.99% | 84.22% | Upgrade
|
| Free Cash Flow Margin | 52.59% | 46.63% | 54.84% | 50.36% | 30.47% | Upgrade
|
| EBITDA | 450.78 | 440.28 | 357.69 | 307.28 | 141.47 | Upgrade
|
| EBITDA Margin | 44.30% | 47.15% | 47.16% | 48.97% | 32.24% | Upgrade
|
| D&A For EBITDA | 11.79 | 19.09 | 19.96 | 23.48 | 25.27 | Upgrade
|
| EBIT | 439 | 421.19 | 337.73 | 283.8 | 116.2 | Upgrade
|
| EBIT Margin | 43.14% | 45.11% | 44.53% | 45.23% | 26.48% | Upgrade
|
| Effective Tax Rate | 18.10% | 20.29% | 13.42% | 24.00% | 6.86% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.